WO2024201423 - MICROTUBULE-ASSOCIATED PROTEIN TAU TARGETING SIRNAS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/201423
Publication Date
03.10.2024
International Application No.
PCT/IB2024/053120
International Filing Date
29.03.2024
Title **
[English]
MICROTUBULE-ASSOCIATED PROTEIN TAU TARGETING SIRNAS AND USES THEREOF
[French]
ARNSI CIBLANT LA PROTÉINE TAU ASSOCIÉE AUX MICROTUBULES ET LEURS UTILISATIONS
Applicants **
BIORCHESTRA CO., LTD.
Inventors
RYU, Jin-Hyeob
PARK, Young Jin
PARK, Suhyeong
LIM, Yu Na
KIM, Insun
KWON, Mincheol
KIM, Jihye
Priority Data
63/493,244
30.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6599 | |
| EPO | Filing, Examination, Granting | 143101 | |
| Japan | Filing, Examination, Granting | 5020 | |
| South Korea | Filing, Examination, Granting | 6356 | |
| USA | Filing, Examination, Granting | 58240 |
Total:
219,316
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to siRNA, which target MAPT transcript in a cell, leading to reduced expression of MAPT protein. Reduction of MAPT protein expression is beneficial for the treatment of certain medical disorders, e.g., a tauopathy.[French]
La présente invention concerne un ARNsi qui cible un transcrit MAPT dans une cellule, conduisant à une expression réduite de la protéine MAPT. La réduction de l'expression de la protéine MAPT est bénéfique pour le traitement de certains troubles médicaux, par exemple, une tauopathie.